Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans (Q34212910)

31 July 2017

title

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans (English)

1 reference

31 July 2017

1 reference

Jean-Simon Diallo

21

0 references

John C Bell

24

object named as

John C Bell

1 reference

31 July 2017

Caroline J Breitbach

1

1 reference

31 July 2017

James Burke

2

1 reference

31 July 2017

Derek Jonker

3

1 reference

31 July 2017

Joe Stephenson

4

1 reference

31 July 2017

Andrew R Haas

5

1 reference

31 July 2017

Laura Q M Chow

6

1 reference

31 July 2017

Jorge Nieva

7

1 reference

31 July 2017

Tae-Ho Hwang

8

1 reference

31 July 2017

Anne Moon

9

1 reference

31 July 2017

Richard Patt

10

1 reference

31 July 2017

Adina Pelusio

11

1 reference

31 July 2017

Fabrice Le Boeuf

12

1 reference

31 July 2017

Joe Burns

13

1 reference

31 July 2017

Laura Evgin

14

1 reference

31 July 2017

Naomi De Silva

15

1 reference

31 July 2017

Sara Cvancic

16

1 reference

31 July 2017

Terri Robertson

17

1 reference

31 July 2017

Ji-Eun Je

18

1 reference

31 July 2017

Yeon-Sook Lee

19

1 reference

31 July 2017

Kelley Parato

20

1 reference

31 July 2017

Aaron Fenster

22

1 reference

31 July 2017

Manijeh Daneshmand

23

1 reference

31 July 2017

David H Kirn

25

1 reference

31 July 2017

language of work or name

English

0 references

publication date

31 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

477

1 reference

31 July 2017

issue

7362

1 reference

31 July 2017

page(s)

99-102

1 reference

https://scigraph.springernature.com/pub.10.1038/nature10358

31 July 2017

exact match

0 references

cites work

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

21 January 2018

Vaccinia virus motility

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Vaccinia virus: a tool for research and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10358

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

21 January 2018

1 reference

12 December 2020

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction

1 reference

12 December 2020

Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF

1 reference

12 December 2020

Primer3 on the WWW for general users and for biologist programmers

1 reference

12 December 2020

Intraperitoneal therapy of ovarian cancer using an engineered measles virus.

1 reference

12 December 2020

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery

1 reference

12 December 2020

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NATURE10358

1 reference

Dimensions Publication ID

31 July 2017

1049165562

0 references

Fatcat ID

release_zoyfxffchnfxxnglhrkinxxeji

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zoyfxffchnfxxnglhrkinxxeji

24 November 2022

mapped directly with Wikidata item

1 reference